Primary:~• To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA)~Secondary:~• To evaluate key clinical outcome assessments
Primary:~• To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA)~Secondary:~• To evaluate key clinical outcome assessments